Rare diseases
Investigational molecules
Locations
Study of Pembrolizumab and Chemotherapy for Patients with HR+/HER2- Advanced Breast Cancer
AustriaDurvalumab versus standard chemotherapy drug combination in elderly patients with advanced non‑small cell lung cancer
ItalyA Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy
CzechiaEvaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study
GreeceStudy of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer
FranceStudy of Pembrolizumab, Carboplatin, and Paclitaxel for Patients with Stage I Triple-Negative Breast Cancer
SpainStudy of Domvanalimab and Zimberelimab Combined with Chemotherapy for Previously Untreated Recurrent or Metastatic Head and Neck Cancer
FranceStudy on the Effectiveness and Safety of Datopotamab Deruxtecan Compared to Chemotherapy in Adults with Advanced Triple-negative Breast Cancer
BelgiumStudy of Livmoniplimab and Budigalimab Compared to Chemotherapy for Adults with Advanced Bladder Cancer
BelgiumStudy of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer
AustriaStudy of low-dose radiation therapy combined with paclitaxel and carboplatin in patients with advanced throat and larynx cancer
PolandStudy of Atezolizumab, Carboplatin, and Paclitaxel for Elderly Patients with Advanced Non-Small Cell Lung Cancer
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
